13 stories tagged with #novo-nordisk, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Novo Nordisk"
Novo Nordisk: Why The Wegovy Pill Doesn't Change My Thesis
Novo Nordisk remains heavily dependent on semaglutide, with 69% of Q1 FY26 revenue tied to this molecule. Learn why NVO stock is a hold.…
Novo Nordisk is taking its new weight loss pill global
Novo Nordisk: Deeply Undervalued With A Return To Growth In 2027
Novo Nordisk is rated a strong buy, offering a 4.2% yield and trading at a 40% discount to fair value. Click here to read more about the NVO stock.…
Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.
Novo's approach to global launches will be guided by patient demand and the strength of healthcare and telehealth infrastructure, the drugmaker said.…
Name tweak could boost GLP-1 access for one in eight women suffering PMOS
Millions of women could soon have greater access to GLP-1 weight loss medications following the global effort to change the name of a hormonal condition that affects 1 in 8 women g…
Weight-Loss Pill Approval Highlights Important Role of PCPs
FDA approval of Eli Lilly’s weight-loss pill on April 1 shows the fast-changing landscape for weight loss, obesity medications.…
EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug
COPENHAGEN — Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc's medicin...…
Novo Nordisk Turns To OpenAI To Tighten Drug Development And Supply Chain - simplywall.st
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
New Eli Lilly weight loss drug has dramatic effects in clinical trial
An experimental anti-obesity injection helped patients reach new levels of weight loss previously only achievable through bariatric surgery, according to new data from the pharmace…
Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant
Novo Nordisk's pipeline positions it closer to Eli Lilly than market sentiment suggests. Click here to see why NVO stock is a Buy.…
Eli Lilly: Novo Nordisk Was Just A Warm-Up
Eli Lilly’s obesity/diabetes outlook: Tirzepatide leads near-term, Retatrutide targets Class III, Foundayo expands maintenance—see 2030 sales & $1,300 PT.…
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
The rejection may make the pharma firms remaining lawsuits more difficult.…
Novo Nordisk’s next obesity battlefront: Winning beyond America
The weight loss pill had a strong U.S. launch this year, and Novo believes that will be replicated in other markets around the world.…